Form 4: Allogene Therapeutics CFO Acquires Shares in Registered Direct Offering

Allogene Therapeutics' CFO, Geoffrey M. Parker, acquired 344,828 shares of common stock in a registered direct offering on May 16, 2024.

Summary

• On May 16, 2024, Geoffrey M. Parker, the Chief Financial Officer of Allogene Therapeutics, Inc., acquired 344,828 shares of common stock.
• The shares were purchased directly from Allogene Therapeutics in a registered direct offering at a price of $2.9 per share.
• Following the transaction, Parker beneficially owns 1,164,418 shares of Allogene Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a factual report of a transaction. The CFO's purchase could be seen as a positive signal, but it's not overwhelmingly so without more context.

Positives

• The CFO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Registered direct offerings are a common way for companies, particularly in the biotech sector, to raise capital. Insider participation can sometimes be viewed positively by the market.

Stakeholder Impact

• The CFO's purchase could potentially increase investor confidence.

Key Dates